Inozyme Story

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:4em;'>IP</div>
INZY -- USA Stock  

USD 26.50  0.15  0.57%

Whilst many millenniums are getting more into healthcare space, it makes sense to break down Inozyme Pharma against current trends within the economy. As we have suggested previously, Inozyme Pharma is beginning its slide as investors shift to be more bearish due to the increased sector volatility. The returns on the market and returns on Inozyme Pharma appear slightly correlated for the last few months. Weak basic indicators of the company may also suggest signs of long term losses for Inozyme investors. Inozyme Pharma is scheduled to announce its earnings today.
Published over a month ago
View all stories for Inozyme Pharma | View All Stories
Our current technical analysis of Inozyme Pharma (NASDAQ:INZY)
The firm's average rating is Strong Buy from 4 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Inozyme Pharma market sentiment investors' perception of the future value of Inozyme. Let us look at a few aspects of Inozyme technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Inozyme Pharma. In general, we focus on analyzing Inozyme Pharma stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Inozyme Pharma's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Inozyme Pharma's intrinsic value. In addition to deriving basic predictive indicators for Inozyme Pharma, we also check how macroeconomic factors affect Inozyme Pharma price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Inozyme Pharma's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Inozyme Pharma in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inozyme Pharma. Your research has to be compared to or analyzed against Inozyme Pharma's peers to derive any actionable benefits. When done correctly, Inozyme Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Inozyme Pharma.

How does Inozyme Stands against Peers?

Analyzing Inozyme Pharma competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Inozyme Pharma across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Inozyme Pharma Competition Details

How Inozyme utilizes its cash?

To perform a cash flow analysis of Inozyme Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Inozyme Pharma is receiving and how much cash it distributes out in a given period. The Inozyme Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Inozyme Pharma Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Inozyme Pharma reported Net Cash Flow from Operations of (16.93 Million) in 2020

Acquisition by Basso Stephen of 41794 shares of Inozyme Pharma subject to Rule 16b-3

Legal trades by Inozyme Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Inozyme insider trading alert for grant of stock option (right to buy) by Basso Stephen, SVP Finance (PFO), on 14th of January 2021. This event was filed by Inozyme Pharma Inc with SEC on 2021-01-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Details

Inozyme Pharma has a beta of -0.7882. Let's try to break down what Inozyme's beta means in this case. The returns on MARKET and Inozyme Pharma are completely uncorrelated. The beta indicator helps investors understand whether Inozyme Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Inozyme deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Net Loss for the year was (22.49 M).

Another 3 percent slide for Inozyme Pharma

Standard deviation is down to 5.01. It may suggest a possible volatility slide. As of the 11th of December 2020, Inozyme Pharma retains the risk adjusted performance of (0.029637), and Market Risk Adjusted Performance of 0.2305. Inozyme Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Inozyme Pharma, which can be compared to its competitors. Please check out Inozyme Pharma value at risk, and the relationship between the jensen alpha and semi variance to decide if Inozyme Pharma is priced fairly, providing market reflects its last-minute price of 22.69 per share. Given that Inozyme Pharma has jensen alpha of (0.08), we strongly advise you to confirm Inozyme Pharma's regular market performance to make sure the company can sustain itself at a future point.

Our Final Takeaway

When is the right time to buy or sell Inozyme Pharma? Buying stocks such as Inozyme Pharma isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily basis. To conclude, as of the 11th of December 2020, we believe Inozyme Pharma is currently undervalued. It moves slightly opposite to the market and projects quite high chance of distress in the next two years. However, our concluding 30 days buy-or-sell advice on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Inozyme Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com